

Forschungsprojekte

Projets de recherche

Unterstützt von:

Krebsliga Schweiz, Oncosuisse

Soutenus par:

Ligue suisse contre le cancer, Oncosuisse

2003

Projektverantwortliche/r Institut	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
<i>Responsable de la recherche Institut</i>	<i>Numero du projet Titre du projet</i>	<i>Durée (mois)</i>	<i>Montant (CHF)</i>
Benhattar Jean , Dr. phil. Institut Universitaire de Pathologie CHUV 1011 Lausanne	KLS 01327-02-2003 Molecular Basis for Neoplastic Progression in Barrett's Esophagus	24	110'700
Borner Markus M. , PD Dr. med. Institut für Medizinische Onkologie Inselspital 3010 Bern	OCS 01333-02-2003 Functional identification of regulators of cancer drug response and apoptosis in ex vivo tissue cultures of human colorectal cancer	24	170'600
Bouchardy Christine , PD Dr. med. + phil. Registre Genevois des Tumeurs 1205 Genève	OCS 01380-02-2003 Epidemiologic research on the impact of genetic factors in breast cancer occurrence among the female population in Geneva: A study from the first familial breast cancer registry in Switzerland	24	219'400
Briskén Cathrin , Dr. Institut Suisse de Recherches Expérimentales sur le Cancer ISREC 1066 Epalinges	OCS 01304-02-2003 A xenograft model for the in vivo study of primary human breast epithelial cells under physiological conditions and during carcinogenesis	12	97'900
Castiglione Monica , Prof. Dr. med. Koordinationszentrum Schweizerisches Institut für angewandte Krebsforschung SIAK / IBCSG Coordinating Center 3008 Bern	OCS 01461-02-2003 IBCSG Medical Fellowship	36	300'000
Constam Daniel , Dr. sc. nat. Institut Suisse de Recherches Expérimentales sur le Cancer ISREC 1066 Epalinges	OCS 01301-02-2003 Mechanism of action of the GPI-anchored proteins Cripto and Cryptic	36	281'700
Dietrich Pierre-Yves , Dr. med. Division d'Oncologie Hôpital Cantonal	OCS 01320-02-2003 The role of JAM-2 in human brain tumors	24	109'100

1211 Genève 14			
Dyson Paul , Prof. Faculté des Sciences de Base Institut de Chimie Moléculaire et Biologique EPFL 1015 Lausanne 15	OCS 01269-08-2002 Rapid identification of proteins targets of drugs from whole cell extracts and subsequent determination of the drug binding site using a novel mass spectrometric approach to provide an understanding of the mechanism of drug action	24	196'000
Garayoa Elisa Garcia , Dr. Paul Scherrer Institute Center for Radiopharmaceutical Science 5232 Villigen	OCS 01311-02-2003 Development of new radiolabelled Bombesin analogues with high tumour to healthy tissues uptake ratios for diagnosis and therapy of prostate and breast cancer	36	135'660
Gasser-Wilson Susan M. , Prof. Dr. Département de Biologie Moléculaire Faculté des Sciences Université de Genève 1211 Genève	OCS 01409-02-2003 DNA Damage checkpoints and genomic instability	24	184'400
Gasser-Wilson Susan M. , Prof. Dr. Département de Biologie Moléculaire Université de Genève 1211 Genève	OCS 01334-02-2003 Identification and characterization of new key proteins involved in the regulation of chromosome condensation throughout the cell cycle: a dual proteomics-microscopy approach.	24	113'100
Greeve Jobst , PD Dr. Inselspital-Universitätsspital Bern Klinik für Allgemeine Innere Medizin 3010 Bern	OCS 01306-02-2003 B cell specific expression of activation- induced cytidine deaminase (AID) in transgenic mice as a model for the molecular pathogenesis of non-Hodgkin's lymphomas	32	170'600
Groettrup Marcus , Prof. Dr. med. Biotechnologie Institut Thurgau (BITg) 8274 Tägerwilen	OCS 01309-02-2003 Regulation of CCR7 signal transduction through prostaglandin E2 and its role for dendritic cell migration and tumor vaccination	24	218'100
Hafen Ernst , Prof. Dr. Zoologisches Institut Entwicklungsbiologie Universität Zürich 8057 Zürich	OCS 01398-02-2003 Genetic and functional analysis of the small GTPase Rheb-Towards the identification of novel drug targets in the TOR signaling pathway	36	167'100
Häffner Andreas , Dr. med. Dermatologische Klinik Universitätsspital Zürich 8091 Zürich	OCS 01318-02-2003 Analysis of Activin A Expression in Non- Melanoma Skin Cancer (NMSC): Influence on Gene Regulation and functional Tumor- Stoma Interactions	24	204'400
Held Werner , Dr. Ludwig Institute for Cancer Research 1066 Epalinges	OCS 01397-02-2003 Tumor cell recognition by natural killer cells	36	293'600
Hemmings Brian S. , Dr. Friedrich Miescher-Institut 4058 Basel	KLS 01342-02-2003 The role of human protein kinase NDR in cell morphogenesis, cell division, growth control and cancer	24	171'700
Huelsken Joerg , Dr. Institut Suisse de Recherches Expérimentales sur le Cancer ISREC 1066 Epalinges	KLS 01616-02-2003 Role of the Wnt signalling pathway in epithelial tumorigenesis: functional analysis, molecular mechanisms and tumor-relevant targets	36	281'700
Imhof Beat A. , Prof. Dr. med. Département de Pathologie	OCS 01335-02-2003 The role of junctional adhesion molecule 2	24	113'100

Centre Médical Universitaire 1211 Genève	(JAM-2) in tumor angiogenesis		
Juillerat-Jeanneret Lucienne , Prof. Dr. Phil. Institut Universitaire de Pathologie CHUV 1011 Lausanne	OCS 01308-02-2003 Photodynamic detection and therapy of cancer: targeting photosensitizers via the glycoside pathways	12	132'300
Krek Wilhelm , Prof. Dr. phil. Institut für Zellbiologie ETH Zürich 8093 Zürich	OCS 01337-02-2003 Roles of SCF-Skp2 ubiquitin protein ligase and associated proteins in cell cycle control and neoplastic signalling	24	216'900
Ludewig Burkhard , PD Dr. med. vet. Laborforschungsabteilung Kantonsspital St. Gallen 9007 St. Gallen	OCS 01317-02-2003 Genetic transduction of dendritic cells with multi-gene murine coronavirus vectors and their application in preclinical tumor vaccination studies	24	210'200
Luescher Immanuel Ludwig Institute for Cancer Research Lausanne Branch 1066 Epalinges	OCS 01421-02-2003 Production of optimized, well-defined soluble peptide/MHC Class I and Class II oligomers for monitoring, isolation and functional analysis of antigen-specific CD8+ and CD4+ T lymphocytes in blood and tumors of melanoma patients enrolled in clinical vaccin	24	201'000
Marino Silvia , Dr. med. Institut für klinische Pathologie Departement Pathologie 8091 Zürich	OCS 01345-02-2003 The role of Bmi1 in cerebellar development and in medulloblastoma pathogenesis	24	201'700
Matthes Thomas , Dr. Division d'Hématologie HUG Genève 1211 Genève	OCS 0112343-02-2003 Interfering in erythroblast differentiation in myelodysplastic syndromes	24	186'700
Merlo Adrian , Prof Neurochirurgische Klinik Universitätsspital 4031 Basel	OCS 01338-02-2003 A combinatorial strategy with "biologicals" against human gliomas. Preclinical study how to exploit novel drugs that target growth 24factor and angiogenic (EGFR, PDGFR, KD24R), integrin (FAK) and nutritional (mTO24R) pathways	24	161'800
Nardelli Haefliger Denise , PD Dr. phil II Département de gynécologie - obstétrique CHUV 1011 Lausanne	OCS 01403-02-2003 Therapeutic vaccination against human papillomavirus type 16 (HPV16) associated high grade anogenital lesions and cancer: Role of the route of immunization.	36	310'100
Neri Dario , Prof. Dr. Institut für Pharmazeutische Wissenschaften ETH-Zürich 8057 Zürich	KLS 01340-02-2003 Isolation and Validation of novel human antibodies for anti-cancer vascular targeting therapeutic strategies	36	90'000
Ochsenbein Adrian Franz , Prof Medizinische Onkologie Inselspital 3010 Bern	OCS 01312-02-2003 Improving adoptive T cell therapy in a murine tumor model that expresses the glycoprotein of lymphocytic choriomeningitis virus as model tumor antigen	24	169'100
Perneger Thomas , Prof. Unité qualité des soins Direction Médicale HUG Hôpitaux Universitaires de Genève 1211 Genève	KLS 01326-02-2003 Communication in cancer screening: effects of amount and content of information on informed choice and the decision-making process	24	144'000
Porzig Hartmut , Prof. Dr. med.	OCS 01404-02-2003	12	104'600

Pharmakologisches Institut Universität Bern 3010 Bern	The role of cytokine- and G protein- dependent signaling for the development of drug resistance in human leukemia cells expressing the Bcr/Abl oncogene		
Redaelli Claudio , PD Dr. med. Department of Visceral Surgery and Transplantation Inselspital 3010 Bern	KLS 01221-02-2002 Adenovirus-mediated gene-transfer of endostatin to inhibit angiogenesis in a rat model of hepatocellular carcinoma	11	62'900
Shore David M. , Prof Faculté des sciences Département de Biologie moléculaire 1211 Genève	OCS 01410-02-2003 Telomere maintenance, DNA damage 24checkpoints and the silencing/aging factor SIR2	36	281'700
Speiser Daniel E. , PD Dr. med. Division d'Onco-Immunologie Institut Ludwig de Recherche sur le Cancer CHUV 1005 Lausanne	OCS 01323-02-2003 Analysis of molecular interactions involved in recognition and killing of tumor cells by human cytolytic lymphocytes	36	289'100
Stagljar Igor , Prof. Dr. Institute of Vet. Biochemistry and Molecular Biology, Functional Genomics University of Zürich 8057 Zürich	OCS 01310-02-2003 The molecular role of the Rothmund- Thomson's helicase (RECQL4) in the maintenance of genome stability in humans	24	167'000
Strasser Florian , Dr. Oncology / Hematology and Palliative Medicine Dep. Internal Medicine Kantonsspital St. Gallen 9007 St. Gallen	OCS 01385-02-2003 Randomised Phase I/II - Study with Ghrelin versus Placebo for patients with cancer- related Anorexia/Cachexia.	12	59'700
Suter Beat , Prof Institut für Zellbiologie 3012 Bern	OCS 01322-02-2003 Cellular control of Cdk7 cell cycle activity (CAK)	24	306'500
Thomas George , PD Dr. Friedrich Miescher-Institut 4002 Basel	KLS 01336-02-2003 The Role of Rheb (Ras homologue enriched in brain) in the mTOR Signaling Pathway and its Involvement in the Pathogenesis of Tuberous Sclerosis Complex Syndrome	24	178'200
Wallimann Theo , Prof. Dr. Institut für Zellbiologie ETH Zürich Hönggerberg HPM 8093 Zürich	OCS 01332-02-2003 Oncogenic alterations of energy metabolism in tumor progression	15	129'500
Widmann Christian , Dr. phil IBCM Universität Lausanne 1005 Lausanne	OCS 01330-02-2003 Design of new tools to improve the efficacy of genotoxins	24	201'000

International Clinical Cancer Research Projects

Franceschi Silvia , Dr. med. Field and Intervention Studies Unit International Agency for Research on Cancer F - 69372 Lyon	ICP OCS 01355-03-2003 Risk of Cancer in Persons Infected with HIV	48	500'000
Heinimann Karl , Dr. med. Research Group Human Genetics Division of Medical Genetics University Children's Hospital Dept. of Clinical & Biological Sciences 4051 Basel	ICP OCS 01358-03-2003 Identification of Multiple Adenoma Susceptibility Genes The IMAGEN Network	48	500'000
Plaschkes Jack , Dr. med. University Childrens Hospital Dept. of Pediatric Surgery Inselspital 3010 Bern	ICP OCS 01405-03-2003 A comprehensive risk-adapted treatment strategy for liver tumours in children and adolescents, consisting of suite of 4 international trials (SIOPEL III-V). (a) Continuation of SIOPEL III, and (b) a study for recurrent and refractory HB, (c) SIOPEL IV: h	36	144'700
Studer Regula International Breast Cancer Study Group Schweizerisches Institut für angewandte Krebsforschung SIAK / IBCSG Coordinating 3008 Bern	ICP OCS 01357-03-2003 International Breast Cancer Study Group (IBCSG)	48	800'000
Zucca Emanuele , Prof. Dr. IOSI-Medical Oncology Dept. Ospedale San Giovanni 6500 Bellinzona	ICP OCS 01356-03-2003 INTERNATIONAL EXTRANODAL STUDY GROUP: A network for improving the understanding and the clinical management of non-Hodgkin's lymphomas arising at extranodal sites	48	500'000

Stipendiengesuche

Bourses de recherche

Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
<i>Candidat/e</i>	<i>Numero du projet Titre du projet</i>	<i>Durée (mois)</i>	<i>Montant (CHF)</i>
Monnier Yan 1012 Lausanne	MD-PhD 01457-12-2003 Role of Cyclooxygenase-2 (COX-2) on Experimental Breast Cancer Progression and Tumor Angiogenesis	36	150'000
Ramseier Christoph , Dr. med. dent. 3012 Bern	BIL OCS 01426-08-2003 Raucher-Kurzintervention in der zahnmedizinischen Praxis: Aus-, Weiter- und Fortbildung des zahnmedizinischen Praxisteams zur Durchführung einer individuellen Raucherprävention und -entwöhnung und Evaluation von Präventions-, Entwöhnungsmethoden und Rauchstop-Raten Columbia University, School of Dental and Oral Surgery, New York	12	20'000
Seiler Daniel , Dr. med. 8805 Richterswil	BIL OCS 01353-02-2003 Molekulare Grundlagen des Androgen- unabhängigen fortgeschrittenen Prostatakarzinoms zur Verlängerung des Tumorprogresses in die hormonrefraktäre Phase University of California, Division of Urologic Oncology, Los Angeles	18	117'000
Sestak Ivana 8304 Wallisellen	BIL KLS 01352-02-2003 Breast Cancer Chemoprevention: Risk- Benefit Profile of Tamoxifen and Anastrozole Queen Mary's School of Medicine and Dentistry, Cancer Research London	24	83'300